CalciMedica CFO Stephen Bardin to resign after Q3 report

The timing links Bardin’s departure to the filing of CalciMedica’s quarterly report for the period ended September 30, 2026.

Rhea-AI Filing Summary

CalciMedica, Inc. (CALC) reported that Stephen Bardin, its Chief Financial Officer, principal accounting officer and principal financial officer, gave notice of resignation on October 15, 2026. His resignation is to take effect immediately following the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. The stated reason is to pursue another professional opportunity, and the resignation was not due to any disagreement with the company.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

principal accounting officer, principal financial officer

2 terms

principal accounting officer financial

"Chief Financial Officer, principal accounting officer and principal financial officer"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

principal financial officer financial

"Chief Financial Officer, principal accounting officer and principal financial officer"

The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is resigning from CALC, and what roles does he hold?

Stephen Bardin, CalciMedica’s Chief Financial Officer, principal accounting officer and principal financial officer, gave notice of resignation on October 15, 2026.

When does Stephen Bardin’s resignation from CALC take effect?

His resignation is to take effect immediately following the filing of CalciMedica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/16/2026 - 04:47 PM EDT Accepted by SEC EDGAR 10/16/2026 - 04:46 PM EDT Learn about SEC filing dates

NASDAQ false 0001534133 0001534133 2026-10-15 2026-10-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2026

CalciMedica, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39538		45-2120079
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

505 Coast Boulevard South, Suite 300-9
La Jolla, California		92037
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 952-5500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CALC		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 15, 2026, Stephen Bardin, the Chief Financial Officer, principal accounting officer and principal financial officer of CalciMedica, Inc. (the “Company”), provided notice of his resignation, to be effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, to pursue another professional opportunity. Mr. Bardin’s resignation was not due to any disagreement with the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						CalciMedica, Inc.
Date: October 16, 2026				By:		/s/ A. Rachel Leheny, Ph. D.
				Name:		A. Rachel Leheny, Ph. D.
				Title:		Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB